微载波
间充质干细胞
生物过程
生物反应器
脐带
胎牛血清
干细胞
生物医学工程
再生医学
细胞培养
细胞生物学
帘布衬里
细胞疗法
间质细胞
化学定义介质
沃顿果冻
化学
免疫学
生物
细胞
细胞分化
工程类
成体干细胞
体外
生物化学
癌症研究
遗传学
有机化学
古生物学
基因
作者
Amanda Mizukami,Ana Fernandes‐Platzgummer,Joana G. Carmelo,Kamilla Swiech,Dimas Tadeu Covas,Joaquim M. S. Cabral,Claudia Lobato da Silva
标识
DOI:10.1002/biot.201500532
摘要
Mesenchymal stem/stromal cells (MSC) are being widely explored as promising candidates for cell-based therapies. Among the different human MSC origins exploited, umbilical cord represents an attractive and readily available source of MSC that involves a non-invasive collection procedure. In order to achieve relevant cell numbers of human MSC for clinical applications, it is crucial to develop scalable culture systems that allow bioprocess control and monitoring, combined with the use of serum/xenogeneic (xeno)-free culture media. In the present study, we firstly established a spinner flask culture system combining gelatin-based Cultispher(®) S microcarriers and xeno-free culture medium for the expansion of umbilical cord matrix (UCM)-derived MSC. This system enabled the production of 2.4 (±1.1) x10(5) cells/mL (n = 4) after 5 days of culture, corresponding to a 5.3 (±1.6)-fold increase in cell number. The established protocol was then implemented in a stirred-tank bioreactor (800 mL working volume) (n = 3) yielding 115 million cells after 4 days. Upon expansion under stirred conditions, cells retained their differentiation ability and immunomodulatory potential. The development of a scalable microcarrier-based stirred culture system, using xeno-free culture medium that suits the intrinsic features of UCM-derived MSC represents an important step towards a GMP compliant large-scale production platform for these promising cell therapy candidates.
科研通智能强力驱动
Strongly Powered by AbleSci AI